05/24/23 4:01 PMNasdaq : DRTS, DRTSW conferencesAlpha Tau Medical to Participate in June Investor ConferencesAlpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences. Event:RHEA-AIneutral
05/23/23 4:01 PMNasdaq : DRTS, DRTSW earningsAlpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer , which began enrolling patient s in March - - Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April - - Results of U.S. multicenter pilot trial in skinRHEA-AIneutral
05/17/23 4:30 PMNasdaq : DRTS, DRTSW clinical trialAlpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge UniversityAlpha Tau Medical Ltd. ("Alpha Tau", or theRHEA-AIneutral
05/11/23 4:00 PMNasdaq : DRTS, DRTSW Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network OpenThe trial demonstrated a 100% Complete Response rate at 12 weeks post treatment and no device-related serious adverse events or systemic toxicity reported in the 10 patients treated in the feasibility and safety study of intratumoral Alpha DaRT for the treatment of recurrent or unresectable skinRHEA-AIneutral
05/03/23 4:00 PMNasdaq : DRTS, DRTSW conferencesAlpha Tau Medical to Present at Guggenheim Radiopharmaceuticals DayAlpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will take part in a fireside chat at theRHEA-AIneutral
04/03/23 9:10 AMNasdaq : DRTS, DRTSW clinical trialAlpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical TrialAlpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), theRHEA-AIneutral
03/29/23 4:00 PMNasdaq : DRTS, DRTSW conferencesAlpha Tau Medical to Present at Jefferies Radiopharma Innovation SummitAlpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will present in-person at the JefferiesRHEA-AIneutral
03/12/23 8:30 AMNasdaq : DRTS, DRTSW Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley BankAlpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today issued the following statement on Silicon Valley Bank (SVB) in response to questions fromRHEA-AIneutral
03/09/23 4:10 PMNasdaq : DRTS, DRTSW earningsAlpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update- Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March - - Received Health Canada approval to initiate a liver cancer feasibility trial - - Pursued supply chain expansion in Israel, the U.S. and Japan, including increases in radioactiveRHEA-AIvery positive
03/08/23 5:00 PMNasdaq : DRTS, DRTSW Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial- First two US patients with recurrent cutaneous squamous cell carcinoma have been treated at University Cancer Center in Houston, Texas -Up to 86 patients to be enrolled in the U.S., Canada, Europe and Israel to assess the efficacy and safety of intratumoral Alpha DaRT for the treatment ofRHEA-AIvery positive
